




Searching News Database: pembrolizumab
HSMN NewsFeed - 23 May 2024
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer
HSMN NewsFeed - 3 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 13 Feb 2020
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial